Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vaxigen Flu H5N8
- Development stage
- Unknown
- Lead developer
- CSL Seqirus
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
vaxigen Flu H5N8 is a recombinant veterinary vaccine developed by Avi-Mex (Laboratorios Avimex) for the immunization of poultry against Avian Influenza caused by the H5N8 subtype. The vaccine utilizes Avi-Mex's proprietary Vaxigen platform, which typically employs a recombinant viral vector (such as Newcastle Disease Virus) to express the hemagglutinin (HA) protein of the target influenza virus. This approach induces a robust and protective immune response in chickens and other poultry species, helping to prevent clinical disease and reduce viral shedding during outbreaks of highly pathogenic avian influenza (HPAI).
- Brand names
- vaxigen Flu H5N8
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on vaxigen Flu H5N8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vaxigen Flu H5N8.